Abstract 3699: Dronedarone is Effective in Maintaining Sinus Rhythm in Atrial Fibrillation Patients in whom Previous Antiarrhythmic Drug Therapy has Failed
Introduction. The EURIDIS and ADONIS studies demonstrated that dronedarone (D), a novel multichannel blocker, is highly effective in promoting long-term sinus rhythm maintenance in AF/AFL patients (pts), with no evidence of extra-cardiac organ toxicities or proarrhythmias.
Objective. The aim of this post-hoc analysis was to evaluate the efficacy of D in reducing recurrences of AF in pts who had taken at least one antiarrhythmic drug (AAD) before randomization and who had stopped for lack of efficacy.
Methods. In EURIDIS/ADONIS, a total of 1,237 pts were randomized in an outpatient setting to receive either D 400 mg bid (n=828) or placebo (P) (n=409) and followed for 12 months. The primary endpoints for both studies were times to first documented AF recurrences detected by ECG or trans-telephonic ECG monitoring. A Cox regression model was used to determine the efficacy of D in pts who had previously failed treatment with class IA, IC or III AADs, or sotalol.
Results. In this analysis, D showed superior efficacy to P in every subgroup (see figure⇓). Adverse events in each subgroup were in line with the consistently favorable overall EURIDIS/ADONIS results.
Conclusion. D is a viable, effective treatment option for AF pts for whom other AADs exhibit poor efficacy in maintaining sinus rhythm.